PMID- 21030345
OWN - NLM
STAT- MEDLINE
DCOM- 20110222
LR  - 20151119
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 10
IP  - 5
DP  - 2010 Oct
TI  - Uncommon or delayed adverse events associated with imatinib treatment for chronic 
      myeloid leukemia.
PG  - 331-5
LID - 10.3816/CLML.2010.n.065 [doi]
AB  - Imatinib, a tyrosine kinase inhibitor, is the first-line therapy for chronic 
      myeloid leukemia (CML). The majority of patients continue treatment for their 
      lifespan because discontinuation generally results in relapse. Many patients 
      treated with imatinib experience adverse events (AEs) at some time during their 
      treatment. Commonly encountered AEs and their management are well known. However, 
      in addition to the common AEs with imatinib, there is a significant number of 
      patients who display either uncommon or delayed AEs. These events can involve 
      cardiac, renal, or dermatologic problems, and fluid retention. Herein, we review 
      these less-than-common side effects and the hazard of administering imatinib 
      during pregnancy. While chronic treatment with imatinib has revolutionized CML 
      prognosis, physicians should be aware of both the common and uncommon adverse 
      reactions.
FAU - Salie, Rishard
AU  - Salie R
AD  - SAN GmbH, Reiden, Switzerland. rishard.salie@sannet.ch
FAU - Silver, Richard T
AU  - Silver RT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Benzamides
MH  - Humans
MH  - Imatinib Mesylate
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
MH  - Piperazines/*administration & dosage/*adverse effects
MH  - Prognosis
MH  - Protein Kinase Inhibitors/adverse effects/therapeutic use
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Pyrimidines/*administration & dosage/*adverse effects
MH  - Treatment Outcome
EDAT- 2010/10/30 06:00
MHDA- 2011/02/23 06:00
CRDT- 2010/10/30 06:00
PHST- 2010/10/30 06:00 [entrez]
PHST- 2010/10/30 06:00 [pubmed]
PHST- 2011/02/23 06:00 [medline]
AID - S2152-2650(11)70198-7 [pii]
AID - 10.3816/CLML.2010.n.065 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):331-5. doi: 10.3816/CLML.2010.n.065.